Apogee International
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Apogee International is a prospective, non-interventional, post-market, multi-site registry, conducted within Medtronic's Product Surveillance Registry (PSR) Platform. Enrollment into Apogee International will be comprised of newly implanted, commercial use patients with the HeartWare Ventricular Assist Device System (HVAD System).
Sites selected to participate are expected to collect data in at least one of these five modules:
- Logfile Download;
- Anti-coagulation / Anti-platelet Management;
- Blood Pressure (BP) Management;
- Acoustic Spectrum Analysis;
- Infection Control
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Sydney, Australia
- St. Vincents Hospital
-
-
-
-
-
Vienna, Austria
- Medical University of Vienna
-
-
-
-
-
Leuven, Belgium
- UZ Leuven - Campus Gasthuisberg
-
-
-
-
-
Aarhus, Denmark
- Aarhus Universitetshospital
-
-
-
-
-
Helsinki, Finland
- Helsinki University Hospital
-
-
-
-
-
Bad Oeynhausen, Germany
- Herz- und Diabeteszentrum NRW - Ruhr-Universität Bochum
-
Bad Rothenfelde, Germany
- Schuechtermann Klinik
-
Berlin, Germany
- Deutsches Herzzentrum Berlin
-
Duesseldorf, Germany
- Universitatsklinikum Dusseldorf
-
Hamburg, Germany
- Universitatsklinikum Hamburg-Eppendorf
-
Hannover, Germany
- Medizinische Hochschule Hannover
-
Leipzig, Germany
- Herzzentrum Leipzig GmbH
-
Magdeburg, Germany
- Otto von Guericke Universitat - Universitätsklinikum Magdeburg
-
Tübingen, Germany
- Eberhard Karls Universität Tübingen - Universitätsklinikum Tübingen
-
-
-
-
-
Bologna, Italy
- Azienda Ospedaliero Universitaria S. Orsola Malpighi Bologna
-
Milano, Italy
- Ospedale San Raffaele
-
Palermo, Italy
- ISMETT
-
-
-
-
-
Astana, Kazakhstan
- National Research Cardiac Surgery Center
-
-
-
-
-
Beirut, Lebanon
- Al Rassoul Al Azam Hospital - Beirut Cardiac Institute
-
-
-
-
-
Leiden, Netherlands
- Leiden Universitair Medisch Centrum (LUMC)
-
Utrecht, Netherlands
- University Medical Center Utrecht
-
-
-
-
-
Oslo, Norway
- Oslo Universitetssykehus-Rikshospitalet
-
-
-
-
-
Warsaw, Poland
- Instytut Kardiologii
-
-
-
-
-
Belgrade, Serbia
- Klinicki Centar Srbije
-
-
-
-
-
A Coruña, Spain
- Hospital Universitario da Coruna
-
Barcelona, Spain
- Hospital Universitari de Bellvitge
-
-
-
-
-
Zürich, Switzerland
- Universitatsspital Zurich
-
-
-
-
-
Ankara, Turkey
- Ankara City Hospital
-
İzmir, Turkey
- Ege Universitesi Tip Fakultesi Hastanesi
-
-
-
-
-
Harefield, United Kingdom
- Royal Brompton & Harefield NHS Foundation Trust - Harefield Hospital
-
Newcastle, United Kingdom
- Freeman Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patient or legally authorized representative provides written authorization and/or consent per institution and geographical requirements;
- Enrollment into Apogee International will be comprised of newly enrolled, commercial use patients with the HeartWare HVAD System;
- Patient is consented prior to the HVAD implant procedure.
Exclusion Criteria:
- Patient who is, or is expected to be inaccessible for follow-up;
- Participation is excluded by local law;
- Patient is currently enrolled or plans to enroll in concurrent drug/device study that may confound the PSR results.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Patients implanted with HVAD System
Patients intended to be implanted with a HeartWare HVAD per the current (local) guidelines, are eligible for enrollment into Apogee International and must be consented for Apogee International prior to the HVAD implant.
|
The HVAD is an implantable centrifugal rotary blood pump that is implanted in the pericardial space and is designed to provide up to 10 L/min of blood flow from the left ventricular to the aorta.
The HVAD System is comprised of three major components: the HVAD (pump) with inflow and outflow conduits, a Controller (microprocessor unit that controls the operation of the HVAD), and power sources (AC and DC power adapters that provide power to the Controller and implanted HVAD).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Major adverse events
Time Frame: Implant to 12 months
|
Major adverse events are defined to be occurrence of major infection, major bleeding, device malfunction, stroke or death.
|
Implant to 12 months
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- Apogee International
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Heart Failure
-
NCT07443969Active, not recruitingHeart Failure | Chronic Heart Failure | Chronic Heart Disease
-
NCT06697353CompletedChronic Heart Failure | Chronic Heart Failure With Reduced Ejection Fraction
-
NCT06632483Active, not recruitingChronic Heart Failure With Reduced Ejection Fraction | Worsening Chronic Heart Failure
-
NCT07369141WithdrawnChronic Heart Failure | Acute Decompensated Heart Failure
-
NCT07490054RecruitingChronic Heart Failure
-
NCT07379840Recruiting
-
NCT07356843RecruitingCongestive Heart Failure | Congestive Heart Failure (CHF) | Congestive Heart Failure Chronic | Congestive Heart Failure(CHF)
-
NCT07350759RecruitingDecompensated Chronic Heart Failure
-
NCT06950320Completed
-
NCT04699253Completed
Clinical Trials on HeartWare Ventricular Assist Device
-
NCT03681210Active, not recruitingChronic Heart Failure
-
NCT03697980CompletedChronic Heart Failure
-
NCT04543747CompletedEnd-stage Heart Failure
-
NCT01001793TerminatedRefractory Heart Failure
-
NCT03583970UnknownHeart Failure | Extracorporeal Membrane Oxygenation | Cardiogenic Shock | Left Ventricular Assist Device
-
NCT00490321UnknownCardiomyopathies | End-stage Heart Failure
-
NCT00483197UnknownCardiomyopathies | End-stage Heart Failure
-
NCT00490347CompletedCardiomyopathies | End-Stage Heart Failure